National guidance (NICE) has a clear recommendation for triple therapy (ICS/LABA/LAMA) for those that have been on dual therapy: For patients who have 1 severe or 2 moderate exacerbations within a year, or have day-to-day symptoms that adversely impact their quality of life1. Triple therapy, however, can be delivered in multiple different ways. The first is through multiple inhaler triple therapy, which there are over 40 different inhaler combinations for ICS/LABA + LAMA, these can include multiple device types and different inhalation techniques. The second is the single inhaler triple therapy options. This webinar will explore these different types of triple therapy available and discuss recent clinical evidence comparing different types of triple therapy, look at some of the potential financial implications, and finally look at some of the potential benefits to both patients and the environment.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on +44 (0)800 221 441
1. NICE Guidance https://www.nice.org.uk/guidance/ng115 accessed Oct 2020
To complete your registration request please fill in the information below
Please fill in the information below to complete registration for this event
We will send you an email confirmation once your booking has been confirmed.